Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium eV, Mannheim, Germany. Breyer J, et al. Among authors: wirtz rm. Clin Genitourin Cancer. 2018 Aug;16(4):248-256.e2. doi: 10.1016/j.clgc.2018.01.009. Epub 2018 Feb 2. Clin Genitourin Cancer. 2018. PMID: 29525349
Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF.
Ebert K, Haffner I, Zwingenberger G, Keller S, Raimúndez E, Geffers R, Wirtz R, Barbaria E, Hollerieth V, Arnold R, Walch A, Hasenauer J, Maier D, Lordick F, Luber B. Ebert K, et al. BMC Cancer. 2022 Mar 9;22(1):254. doi: 10.1186/s12885-022-09335-4. BMC Cancer. 2022. PMID: 35264144 Free PMC article.
Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
Mayr R, Eckstein M, Wirtz RM, Santiago-Walker A, Baig M, Sundaram R, Carcione JC, Stoehr R, Hartmann A, Bolenz C, Burger M, Otto W, Erben P, Breyer J. Mayr R, et al. Among authors: wirtz rm. Eur Urol. 2022 Jun;81(6):606-614. doi: 10.1016/j.eururo.2022.02.028. Epub 2022 Mar 26. Eur Urol. 2022. PMID: 35351346 Free article.
Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.
Psyrri A, Kalogeras KT, Wirtz RM, Kouvatseas G, Karayannopoulou G, Goussia A, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Koutras A, Lazaridis G, Christodoulou C, Pentheroudakis G, Economopoulou P, Laskarakis A, Arapantoni-Dadioti P, Batistatou A, Sotiropoulou M, Aravantinos G, Papakostas P, Kosmidis P, Pectasides D, Fountzilas G. Psyrri A, et al. Among authors: wirtz rm. J Transl Med. 2017 Feb 13;15(1):30. doi: 10.1186/s12967-017-1134-7. J Transl Med. 2017. PMID: 28193231 Free PMC article. Clinical Trial.
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial.
Witzel I, Loibl S, Wirtz R, Fasching PA, Denkert C, Weber K, Lück HJ, Huober J, Karn T, Mackelenbergh MV, Marmé F, Schem C, Stickeler E, Untch M, Müller V. Witzel I, et al. Br J Cancer. 2019 Dec;121(12):1009-1015. doi: 10.1038/s41416-019-0630-3. Epub 2019 Nov 15. Br J Cancer. 2019. PMID: 31728025 Free PMC article. Clinical Trial.
151 results